# Iron Intravenous Therapy in Reducing the Burden of Severe Arrhythmias in Heart Failure With Reduced Ejection Fraction

> **NCT04974021** · — · UNKNOWN · sponsor: **Aristotle University Of Thessaloniki** · enrollment: 106 (actual)

## Conditions studied

- Ferric Carboxymaltose
- Heart Failure With Reduced Ejection Fraction
- Arrhythmias, Cardiac

## Interventions

- **DRUG:** Ferric carboxymaltose

## Key facts

- **NCT ID:** NCT04974021
- **Lead sponsor:** Aristotle University Of Thessaloniki
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-20
- **Primary completion:** 2021-08-30
- **Final completion:** 2021-09-30
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2021-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04974021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04974021, "Iron Intravenous Therapy in Reducing the Burden of Severe Arrhythmias in Heart Failure With Reduced Ejection Fraction". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04974021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*